☆ 4.4 Editorial Material

The latest advancements in Zika virus vaccine development

EXPERT REVIEW OF VACCINES (2017)

获取全文
添加到收藏夹

期刊

EXPERT REVIEW OF VACCINES
卷 16, 期 10, 页码 951-954

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2017.1363648

关键词

Flavivirus; Zika virus; vaccine; advancement; challenge

类别

Immunology

资金

  1. NIAID NIH HHS [U19 AI171954] Funding Source: Medline

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Immunology

SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Xinling Wang, Wei Xu, Gaowei Hu, Shuai Xia, Zhiping Sun, Zezhong Liu, Youhua Xie, Rong Zhang, Shibo Jiang, Lu Lu

CELLULAR & MOLECULAR IMMUNOLOGY (2023)

添加到收藏夹
Letter Cell Biology

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Shuai Xia, Jasper Fuk-Woo Chan, Lijue Wang, Fanke Jiao, Kenn Ka-Heng Chik, Hin Chu, Qiaoshuai Lan, Wei Xu, Qian Wang, Chao Wang, Kwok-Yung Yuen, Lu Lu, Shibo Jiang

CELL RESEARCH (2022)

添加到收藏夹
Editorial Material Immunology

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern

Shan Su, Weihua Li, Shibo Jiang

Summary: The simultaneous presence of SARS-CoV-2 and MERS-CoV raises concerns about the potential emergence of new beta-coronavirus strains with high transmissibility similar to SARS-CoV-2 and high mortality rates similar to MERS-CoV. Therefore, there is an urgent need to develop pan-beta-CoV vaccines capable of targeting not only current variants of concern, but also potential future coronaviruses resembling SARS-CoV-3 or MERSCoV-2.

TRENDS IN IMMUNOLOGY (2022)

添加到收藏夹
Article Virology

A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines

Naru Zhang, Kangchen Li, Zezhong Liu, Kutty Selva Nandakumar, Shibo Jiang

Summary: This article focuses on the research progress and achievements of adjuvanted COVID-19 subunit and inactivated vaccines, and compares the advantages and disadvantages of different adjuvant formulations, aiming to provide a scientific reference for designing an effective strategy for future vaccine development.

VIRUSES-BASEL (2022)

添加到收藏夹
Article Microbiology

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells

Xinling Wang, Wei Xu, Zezhong Liu, Yanling Wu, Qian Wang, Miao Cao, Tianlei Ying, Na He, Lu Lu, Shibo Jiang

Summary: In this study, a dual-targeting recombinant protein, DL35D, was designed and constructed to simultaneously target HIV-1 virus and latent cells. DL35D-DM1, produced by linking the DM1 toxin to DL35D, showed inhibitory and inactivation activity against HIV-1 infection and effectively killed HIV-1-infected cells and LRA-reactivated latent cells, making it a promising candidate for the development of a novel antiviral drug for potential HIV functional cure.

MBIO (2022)

添加到收藏夹
Article Immunology

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

Xun Wang, Xiaoyu Zhao, Jieyu Song, Jing Wu, Yuqi Zhu, Minghui Li, Yuchen Cui, Yanjia Chen, Lulu Yang, Jun Liu, Huanzhang Zhu, Shibo Jiang, Pengfei Wang

Summary: This study found that the Omicron variant is highly resistant to neutralization by sera from convalescents or individuals vaccinated with two doses of inactivated whole-virion vaccines. However, a homologous or heterologous booster significantly increased neutralization titers. Additionally, the Omicron variant resists most monoclonal antibodies targeting distinct epitopes. These findings highlight the importance of pushing forward booster vaccinations to combat emerging SARS-CoV-2 variants.

EMERGING MICROBES & INFECTIONS (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

Cheng Li, Wuqiang Zhan, Zhenlin Yang, Chao Tu, Gaowei Hu, Xiang Zhang, Wenping Song, Shujuan Du, Yuanfei Zhu, Keke Huang, Yu Kong, Meng Zhang, Qiyu Mao, Xiaodan Gu, Yi Zhang, Youhua Xie, Qiang Deng, Yuanlin Song, Zhenguo Chen, Lu Lu, Shibo Jiang, Yanling Wu, Lei Sun, Tianlei Ying

Summary: This study identifies two highly conserved regions on the Omicron variant receptor-binding domain that are recognized by broadly neutralizing antibodies, and generates a bispecific antibody that can simultaneously bind these regions, showing excellent therapeutic efficacy and neutralization breadth.

CELL (2022)

添加到收藏夹
Article Chemistry, Medicinal

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

Huan Wang, Xinling Wang, Jiahui Li, Qing Li, Siliang Feng, Lu Lu, Chao Wang, Shibo Jiang

Summary: Both the deep pocket region and its neighboring subpocket site on the N-trimer of HIV-1 gp41 protein can be targeted for the development of HIV-1 entry inhibitors. This study reports the design of alpha-helical lipopeptides with non-native protein sequences as highly active HIV-1 fusion inhibitors that can occupy both the deep pocket and subpocket sites.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹
Article Chemistry, Medicinal

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile

Wei Xu, Zhe Cong, Qianyu Duan, Qian Wang, Shan Su, Rui Wang, Lu Lu, Jing Xue, Shibo Jiang

Summary: A protein-based, long-acting HIV fusion inhibitor called FLT was designed and constructed, which binds with human serum albumin in a reversible manner to prolong the half-life of the HIV fusion inhibitor T1144. FLT showed high efficiency in inhibiting HIV infection and is considered a promising candidate for a new protein-based anti-HIV drug.

PHARMACEUTICALS (2022)

添加到收藏夹
Article Virology

Rock1 is a novel host dependency factor of human enterovirus A71: Implication as a drug target

Xiaoyu Zhao, Cun Li, Man Chun Chiu, Rui Qiao, Shibo Jiang, Pengfei Wang, Jie Zhou

Summary: In this study, potent inhibitors against EV-A71 infection were identified through screening a kinase inhibitor library. Among the hits, the Rock inhibitor GSK269962A was found to efficiently suppress EV-A71 replication in RD cells and human intestinal organoids in a dose-dependent manner. Knockdown of Rock1, but not Rock2, significantly restricted viral replication in RD cells, suggesting that Rock1 could serve as a novel host dependency factor and target for the development of anti-EV-A71 therapeutics.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹
Review Immunology

Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines

Xiaoqing Guan, Yang Yang, Lanying Du

Summary: The COVID-19 pandemic has caused significant damage to both humans and the economy, and vaccination is crucial in controlling the spread of the virus. The spike protein of SARS-CoV-2, particularly the receptor-binding domain (RBD), is an important target for vaccines. This review discusses the structure and function of the spike protein and its RBD, current COVID-19 vaccines targeting the RBD, and potential strategies for improving RBD-based vaccines. The information provided in this review is important for the rational design and development of safer and more effective COVID-19 vaccines.

EXPERT REVIEW OF VACCINES (2023)

添加到收藏夹
Article Virology

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Chao Wang, Qing Li, Lujia Sun, Xinling Wang, Huan Wang, Wenpeng Zhang, Jiahui Li, Yang Liu, Lu Lu, Shibo Jiang

Summary: Researchers developed a novel dual-target inhibitor by integrating a small-molecule HIV-1 inhibitor with an artificial peptide. This inhibitor showed improved activity against multiple drug-resistant HIV-1 strains.

VIRUSES-BASEL (2023)

添加到收藏夹
Article Biochemistry & Molecular Biology

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies

Ling Xu, Chao Wang, Wei Xu, Lixiao Xing, Jie Zhou, Jing Pu, Mingming Fu, Lu Lu, Shibo Jiang, Qian Wang

Summary: By replacing the PEG linker in EK1C4 with a short peptide, we designed and synthesized a dePEGylated lipopeptide, EKL1C, which showed potent inhibitory activity against coronaviruses, including SARS-CoV-2, and HIV-1. This indicates that HR1 may serve as a common target for the development of broad-spectrum viral fusion inhibitors, and EKL1C has potential clinical application as a therapeutic or preventive agent against coronavirus, HIV-1, and other class I enveloped viruses.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹
Article Biochemistry & Molecular Biology

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

Xiaojie Su, Ziqi Huang, Wei Xu, Qian Wang, Lixiao Xing, Lu Lu, Shibo Jiang, Shuai Xia

Summary: The peptide-based pan-coronavirus fusion inhibitor EK1 is showing promising clinical application prospects against SARS-CoV-2 and its variants. By conjugating EK1 with the human immunoglobulin G Fc-binding peptide (IBP), the engineered peptide IBP-EK1 demonstrates broad-spectrum inhibitory activity against various coronaviruses with improved in vivo half-life. It also shows synergistic effects when combined with monoclonal neutralizing antibodies, suggesting its potential as a long-acting, broad-spectrum antiviral agent against COVID-19 and future highly pathogenic coronaviruses.

BIOMOLECULES (2023)

添加到收藏夹
Article Multidisciplinary Sciences

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge

Xiaoqing Guan, Abhishek K. Verma, Gang Wang, Juan Shi, Stanley Perlman, Lanying Du

Summary: Intranasal delivery of a glycosylated Delta variant receptor-binding domain mucosal vaccine elicited potent systemic and mucosal antibody responses, protecting mice from lethal challenge. Additionally, combining intramuscular priming with intranasal boosting improved the vaccine's ability to generate neutralizing antibodies against recent Omicron variants.

ISCIENCE (2023)

添加到收藏夹
暂无数据
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.